Clinical and Pathological Analysis of the Kidney in Patients with Hypertensive Nephropathy

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2013 Nov 14

PMID 24223652

Citations 18

Authors

Xiang-Chuan Wang

Chun-Hui Liu

Yun-Jing Chen

Yang Wu

Lei-Shan Yang

Hong-Min Liu

Hai-Li Liao

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to identify the association between pathological types of kidney and clinical manifestations in patients with hypertensive nephropathy. The blood pressure, fundus, urinalysis test results and renal function changes were analysed in patients who were treated for hypertensive nephropathy. Downward kidney puncture biopsy was performed using a 16G ejection needle with the aid of B ultrasound in 47 cases. The specimens were observed using light microscopy and immunofluorescence. The pathological changes observed in the patients exhibiting symptoms of hypertensive nephropathy varied. The majority of clinical manifestations were benign arteriolar nephrosclerosis, hyaline degeneration of the renal artery and the appearance of a thickened wall of a thickened renal artery wall. Severe cases showed malignant arteriolar nephrosclerosis characterised by fibrinoid necrosis of renal arterioles and intimal hyperplasia. In addition, in the severe cases, fibrinoid necrosis of the afferent arteriole and arcuate artery wall was observed, with severe interlobular artery and arcuate artery myointimal thickening. Renal biopsy in patients with hypertensive nephropathy is safe and feasible. The prognosis and treatment of pathological and clinical disease related to renal pathology is necessary.

Citing Articles

URINARY NEPHRIN AS AN EARLY BIOMARKER OF HYPERTENSIVE NEPHROPATHY.

Kostovska I, Tosheska Trajkovska K, Labudovic D, Kostovski O Acta Clin Croat. 2025; 62(4):635-643.

PMID: 39866768 PMC: 11759126. DOI: 10.20471/acc.2023.62.04.8.

Epigenetics of Hypertensive Nephropathy.

Zhang Y, Arzaghi H, Ma Z, Roye Y, Musah S Biomedicines. 2024; 12(11).

PMID: 39595187 PMC: 11591919. DOI: 10.3390/biomedicines12112622.

Supramolecular dye nanoassemblies for advanced diagnostics and therapies.

Ramezani P, De Smedt S, Sauvage F Bioeng Transl Med. 2024; 9(4):e10652.

PMID: 39036081 PMC: 11256156. DOI: 10.1002/btm2.10652.

Activation of Pannexin-1 channels causes cell dysfunction and damage in mesangial cells derived from angiotensin II-exposed mice.

Lucero C, Navarro L, Barros-Osorio C, Caceres-Conejeros P, Orellana J, Gomez G Front Cell Dev Biol. 2024; 12:1387234.

PMID: 38660621 PMC: 11041381. DOI: 10.3389/fcell.2024.1387234.

Dapagliflozin-entresto protected kidney from renal hypertension via downregulating cell-stress signaling and upregulating SIRT1/PGC-1α/Mfn2-medicated mitochondrial homeostasis.

Ko S, Yang C, Sung P, Cheng B, Shao P, Chen Y Exp Biol Med (Maywood). 2023; 248(23):2421-2439.

PMID: 38059322 PMC: 10903247. DOI: 10.1177/15353702231198087.

References

Barrett-OKeefe Z, Witman M, McDANIEL J, Fjeldstad A, Trinity J, Ives S . Angiotensin II potentiates α-adrenergic vasoconstriction in the elderly. Clin Sci (Lond). 2012; 124(6):413-22. DOI: 10.1042/CS20120424. View

Ikee R, Kobayashi S, Saigusa T, Namikoshi T, Yamada M, Hemmi N . Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res. 2006; 29(1):15-22. DOI: 10.1291/hypres.29.15. View

Redon J, Pascual J . Development of microalbuminuria in essential hypertension. Curr Hypertens Rep. 2006; 8(2):171-7. DOI: 10.1007/s11906-006-0015-x. View

Romain T, Patel R, Heaberlin A, Zarowitz B . Assessment of factors influencing blood pressure control in a managed care population. Pharmacotherapy. 2003; 23(8):1060-70. DOI: 10.1592/phco.23.8.1060.32879. View

Yui Y, Kodama K, Hirayama A, Hosoda S, Kawai C . Estimated glomerular filtration rate reversal by blood pressure lowering in chronic kidney disease: Japan Multicenter Investigation for Cardiovascular DiseaseB CKD study. J Clin Hypertens (Greenwich). 2013; 15(3):171-5. PMC: 8033949. DOI: 10.1111/jch.12054. View

Hill G . Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 2008; 17(3):266-70. DOI: 10.1097/MNH.0b013e3282f88a1f. View

Mene P, Punzo G . Uric acid: bystander or culprit in hypertension and progressive renal disease?. J Hypertens. 2008; 26(11):2085-92. DOI: 10.1097/HJH.0b013e32830e4945. View

Heim A, Pasche A, Feihl F, Liaudet L, Waeber B . [Hypertension: early detection of target organ damage]. Rev Med Suisse. 2007; 3(124):1996, 1999-2002. View

Flack J, Peters R, Shafi T, Alrefai H, Nasser S, Crook E . Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol. 2003; 14(7 Suppl 2):S92-8. DOI: 10.1097/01.asn.0000070142.14843.8e. View

10.

Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R . Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int Suppl. 2005; (99):S52-6. DOI: 10.1111/j.1523-1755.2005.09910.x. View

11.

Tso M, Jampol L . Pathophysiology of hypertensive retinopathy. Ophthalmology. 1982; 89(10):1132-45. DOI: 10.1016/s0161-6420(82)34663-1. View

12.

Epstein M, Calhoun D . The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep. 2007; 9(2):98-105. DOI: 10.1007/s11906-007-0018-2. View

13.

Masuo K . Obesity-related hypertension: role of the sympathetic nervous system, insulin, and leptin. Curr Hypertens Rep. 2002; 4(2):112-8. DOI: 10.1007/s11906-002-0035-0. View

14.

Mule G, Cottone S, Cusimano P, Incalcaterra F, Giandalia M, Costanzo M . Inverse relationship between ambulatory arterial stiffness index and glomerular filtration rate in arterial hypertension. Am J Hypertens. 2007; 21(1):35-40. DOI: 10.1038/ajh.2007.10. View

15.

Hansson L . The effect of dihydropyridine calcium antagonists in hypertensive patients with impaired renal function. J Cardiovasc Pharmacol. 1989; 14 Suppl 10:S36-9; discussion S59-62. View

16.

Poudel B, Yadav B, Shrestha R, Mittal A, Jha B, Raut K . Assessment of chronic kidney disease in Nepalese people with hypertension. Nepal Med Coll J. 2013; 14(1):25-30. View

17.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J . The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005; 165(8):947-53. DOI: 10.1001/archinte.165.8.947. View